Diabetes Care Drugs News

Related Pharmaceuticals Industry News

• July 2022: Fagron, the leading global player in pharmaceutical compounding, acquired a 503B outsourcing facility from Fresenius Kabi in Boston. With this acquisition, Fagron expanded its United States sterile compounding footprint.
• June 2022: Osceola Capital, a private equity firm, announced the eighth addition to the Revelation Pharma Corporation platform by purchasing Wedgewood Pharmacy’s human health book of business. Wedgewood Pharmacy operates compounding pharmacies that offer sterile and non-sterile compounded medications for animal patients in 50 states.

• April 2022: Pfizer Inc. announced plans to open the first U.S. sites in the Phase 3 study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne muscular dystrophy (DMD).
• May 2022: Stealth BioTherapeutics Corp. announced that the FDA has granted orphan drug designation to elamipretide for treating Duchenne muscular dystrophy.

• October 2022: Bausch Health Companies Inc. implemented changes to the Tabular Index for the prevention and treatment of SAD as per the Centers for Medicare & Medicaid Services (CMS) guidelines. Consequently, all relevant codes have been consolidated into a unified bundle for SAD. This modification facilitates healthcare professionals in providing a more straightforward diagnosis through an easily accessible index tab, condensing all SAD diagnoses into one simplified code: F33.
• February 2022: Granules India received approval from the United States Food and Drug Administration to market Bupropion Hydrochloride extended-release tablets in the United States to treat major depressive disorder and seasonal affective disorder.

• In January 2023, Daewoong Pharmaceutical signed an agreement with CS Pharmaceuticals for a first-in-class PRS inhibitor Bersiporocin in Greater China, including mainland China, Hong Kong, Taiwan, and Macau. Under this agreement, CSP will in-license bersiporocin for idiopathic pulmonary fibrosis (IPF) and potentially other fibrotic indications for a total consideration of up to USD 336 million, including up to USD 76 million in upfront and development milestone payments and double-digit royalties on net sales.
• In May 2022, Sandoz launched generic pirfenidone, an AB-rated (fully substitutable) equivalent to Genentech's Esbriet, to treat patients with idiopathic pulmonary fibrosis (IPF) in the United States.

• January 2023: Medterra launched its newest product, Natural Pain Relief capsules. Medterra Natural Pain Relief is a clinically proven, plant-based pain reliever formulated to alleviate muscle pain, joint stiffness, and inflammation without the negative side effects often associated with over-the-counter (OTC) options.
• January 2023: Ratiopharm, a German pharmaceutical company, launched an over-the-counter combination pain reliever named Synofen, which contains 200 mg ibuprofen and 500 mg paracetamol.

• In April 2023, Everest Medicines received the approval of Nefecon, a primary immunoglobulin A nephropathy (IgAN) drug, from the Hainan Medical Products Administration for clinical use in China.
• In March 2022, Grifols received approval from several European Union member state health authorities as well as from the United Kingdom for XEMBIFY. It is an innovative 20% subcutaneous immunoglobulin (SCIG) that has been approved to treat primary and selected secondary immunodeficiencies.

• March 2023: CAPED and Roche Diagnostics signed a Memorandum of Understanding (MoU) with the Cancer Awareness Prevention and Early Detection Trust (CAPED), a non-profit organization that promotes cancer awareness, prevention, and early detection. The partnership aimed to launch a Cervical Cancer screening program in India.
• February 2023: Australia switched from two doses to a single dose of the Gardasil 9 human papillomavirus vaccine for routine immunization of young people under the National Immunisation Program.

• In July 2022, Stallergenes Greer, a global healthcare company that specializes in allergen immunotherapy (AIT), announced the positive data related to the significant benefit of sublingual liquid allergen immunotherapy treatment (AIT) on the onset and worsening of asthma in patients with allergic rhinitis. 
• In March 2022, Aravax Pty Ltd announced the opening of investigational new drug (IND) application for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy

• February 2023: Metrc reported the expansion of its contract with the State of Missouri to support the regulation of its adult-use cannabis market.
• April 2022: Seven medical-marijuana companies received approval to start selling their products to all adults, opening the door to the first legal marijuana sales in the New York City region within a month.

• In January 2023, Luye Pharma Group received the Food and Drug Administration approval for Rykindo with the aim to treat Schizophrenia and bipolar 1 disorder.
• In February 2022, Alkermes plc released positive results from ENLIGHTEN-early, a phase 3b study that evaluate the study of LYBALVI in schizophrenia disease.
• In January 2022, Otsuka Pharmaceutical Co., Ltd., its subsidiary Otsuka American Pharmaceutical, Inc., and Lundbeck, Inc. received the Food and Drug Administration approval for the supplemental new drug application of REXULTI for Schizophrenia in 13 to 17-year-old patients.